Liraglutide
- Generic Name
- Liraglutide
- Brand Names
- Saxenda, Victoza, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 204656-20-2
- Unique Ingredient Identifier
- 839I73S42A
- Background
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining...
- Indication
Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m), or who are overweight (BMI≥27 kg/m) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years ol...
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT00993720
- Locations
- 🇩🇰
Hvidovre University Hospital, Hvidovre, Denmark
Safety and Tolerability of NN9068 in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT00983021
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers
- First Posted Date
- 2009-09-16
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 49
- Registration Number
- NCT00978393
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Maastricht, Netherlands
Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 21
- Registration Number
- NCT00943501
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir
- Conditions
- Interventions
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 33
- Registration Number
- NCT00873223
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Chula Vista, California, United States
The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 987
- Registration Number
- NCT00856986
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Welwyn Garden City, United Kingdom
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance
- Conditions
- Interventions
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 422
- Registration Number
- NCT00781937
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Montreal, Canada
To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 37
- Registration Number
- NCT00761540
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 665
- Registration Number
- NCT00700817
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
- Conditions
- Interventions
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 415
- Registration Number
- NCT00696657
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Trowbridge, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.